| Literature DB >> 28724544 |
Amanda R Campbell1,2, Megan C Duggan1,2, Lorena P Suarez-Kelly1, Neela Bhave1, Kallan S Opheim1, Elizabeth L McMichael1,2, Prashant Trikha1, Robin Parihar1, Eric Luedke1,3, Adrian Lewis1, Bryant Yung4, Robert Lee4, David Raulet5, Susheela Tridandapani6, Veronika Groh7, Lianbo Yu8, Vedat Yildiz8, John C Byrd1,9, Michael A Caligiuri1,9, William E Carson10,3.
Abstract
Natural killer (NK) cells are large granular lymphocytes that promote the antitumor response via communication with other cell types in the tumor microenvironment. Previously, we have shown that NK cells secrete a profile of immune stimulatory factors (e.g., IFNγ, MIP-1α, and TNFα) in response to dual stimulation with the combination of antibody (Ab)-coated tumor cells and cytokines, such as IL12. We now demonstrate that this response is enhanced in the presence of autologous monocytes. Monocyte enhancement of NK cell activity was dependent on cell-to-cell contact as determined by a Transwell assay. It was hypothesized that NK cell effector functions against Ab-coated tumor cells were enhanced via binding of MICA on monocytes to NK cell NKG2D receptors. Strategies to block MICA-NKG2D interactions resulted in reductions in IFNγ production. Depletion of monocytes in vivo resulted in decreased IFNγ production by murine NK cells upon exposure to Ab-coated tumor cells. In mice receiving trastuzumab and IL12 therapy, monocyte depletion resulted in significantly greater tumor growth in comparison to mock-depleted controls (P < 0.05). These data suggest that NK cell-monocyte interactions enhance NK cell antitumor activity in the setting of monoclonal Ab therapy for cancer. Cancer Immunol Res; 5(9); 778-89. ©2017 AACR. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28724544 PMCID: PMC5581690 DOI: 10.1158/2326-6066.CIR-16-0005
Source DB: PubMed Journal: Cancer Immunol Res ISSN: 2326-6066 Impact factor: 11.151